Home
Abbisko Therapeutics

Abbisko Therapeutics Market Share Analysis for June 2026

Industry: N/A

Domainabbisko.com

Year Founded2016

Employees51 - 200

Annual Revenue$10M - $15M

Abbisko Therapeutics

Abbisko Therapeutics (including company regionals)

abbisko.com

See more website traffic and engagement information

Abbisko Therapeutics Revenue up to June 2026 is 10M - 15M

revenue generated by Abbisko Therapeutics top domains

Abbisko Therapeutics top domains revenue over 3 years

Revenue for Abbisko Therapeutics top domains

abbisko.com10M - 15M

See more with Sales Intelligence

Total visits to Abbisko Therapeutics's top domains

Understand Abbisko Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

abbisko.com617

See more with Sales Intelligence

Avg. visit duration in Abbisko Therapeutics's top domains

Analyze Abbisko Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

abbisko.com00:00:35

See more with Sales Intelligence

Avg. pageviews on Abbisko Therapeutics's top domains

See how Abbisko Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

abbisko.com2.68

See more with Sales Intelligence

Abbisko Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Abbisko Therapeutics

These are the website technologies, by industry, used by Abbisko Therapeutics top domains

Mobile (3)

Meta Viewport

Advertising (2)

PubMatic

Widget (1)

Baidu Maps

News & Signals from Abbisko Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAbbisko Therapeutics Co., Ltd. is developing novel IO-TKI combination therapy for non-small cell lung cancer on Jul 1st '26.SHANGHAI, July 1, 2026 /PRNewswire/ - Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC).

NewsAbbisko Therapeutics Co., Ltd. is developing several drug programs on Jun 24th '26.Under the terms of the agreement, Abbisko will lead the discovery and early development of several drug programs directed at disease targets selected by Lilly.